Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

NCT01251861 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

108

Enrollment

NIH

Sponsor class

Conditions

Recurrent Prostate Carcinoma
Stage I Prostate Cancer AJCC v7
Stage IIA Prostate Cancer AJCC v7
Stage IIB Prostate Cancer AJCC v7
Stage III Prostate Cancer AJCC v7

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Bicalutamide
OTHER: Clinical Observation
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)